{
    "clinical_study": {
        "@rank": "154583", 
        "acronym": "ATM-Cog", 
        "arm_group": [
            {
                "arm_group_label": "Atomoxetine", 
                "arm_group_type": "Active Comparator", 
                "description": "The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients in the placebo arm will follow the same titration schedule as those in teh active arm.  Patients will titrate up to target dose by starting 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose to 80mg daily."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and effectiveness of a drug called\n      atomoxetine for the treatment of cognitive impairment for Parkinson 's disease.  Atomoxetine\n      (ATM) is an approved drug currently on the market for the treatment of attention deficit.\n      It works to increase the amount of norepinephrine (a chemical in the brain that helps keep\n      us awake and alert) in our brain. ATM has not been approved by the Food and Drug\n      Administration (FDA) to be used in the treatment of PD."
        }, 
        "brief_title": "Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Parkinson's Disease", 
            "Cognitive Impairment"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Parkinson Disease", 
                "Cognition Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of idiopathic PD according to the UK PD Society Brain\n             Bank(UKPDSBB) criteria\n\n          -  Male or female subjects aged between 35 and 75 years, inclusive at the time of\n             consent\n\n          -  Hoehn & Yahr Stage I-IV\n\n          -  Diagnosis of PD MCI, Montreal Cognitive Assessment (MoCa) score 21-25\n\n          -  Stable concomitant medications for 60 days\n\n        Exclusion Criteria:\n\n          -  Secondary parkinsonism or atypical parkinsonism,  Prior DBS or other brain surgery\n\n          -  PD Dementia; MoCA score <21\n\n          -  Presence of Psychosis, pregnancy, suicidal ideation on the C-SSRS type 4 or 5 in past\n             3 months.\n\n          -  Current treatment with anticholinergics, MAO inhibitors or neuroleptics (including\n             quetiapine)\n\n          -  Serious cardiac abnormalities,  Narrow angle glaucoma, Pheochromocytoma, Bipolar\n             Disorder\n\n          -  LFTs>1.5 X upper limit of normal value"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738191", 
            "org_study_id": "ATM-Cog"
        }, 
        "intervention": [
            {
                "arm_group_label": "Atomoxetine", 
                "description": "The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.", 
                "intervention_name": "Atomoxetine", 
                "intervention_type": "Drug", 
                "other_name": "Strattera"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Atomoxetine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Parkinson's disease", 
        "lastchanged_date": "November 29, 2012", 
        "location": {
            "contact": {
                "email": "zimmerj@musc.edu", 
                "last_name": "Jennifer Zimmerman, RN, BSN", 
                "phone": "843-792-9115"
            }, 
            "facility": {
                "address": {
                    "city": "Charleston", 
                    "country": "United States", 
                    "state": "South Carolina", 
                    "zip": "29425"
                }, 
                "name": "Medical University of South Carolina"
            }, 
            "investigator": {
                "last_name": "Vanessa Hinson, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)", 
        "other_outcome": {
            "description": "To examine clinical predictors of response to ATM therapy. We will examine four groups of baseline predictors of outcome on the above primary measures:\nCognitive impairment (Montreal Cognitive Assessment (MoCA score), PD motor symptoms (Unified Parkinson's Disease Rating Scale (UPDRS), Quality of life (Parkinson's Disease Questionnaire (PDQ-39), and Mood disturbance (Geriatric Depression Scale (GDS), Geriatric Anxiety Scale (GAI).", 
            "measure": "Clinical predictors", 
            "safety_issue": "No", 
            "time_frame": "Throughout 12 week time period"
        }, 
        "overall_contact": {
            "email": "zimmerj@musc.edu", 
            "last_name": "Jennifer Zimmerman, RN, BSN", 
            "phone": "843-792-9115"
        }, 
        "overall_official": {
            "affiliation": "Medical University of South Carolina", 
            "last_name": "Vanessa Hinson, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To examine in a 12-week, single-site, parallel, randomized, double-blind, placebo-controlled trial the efficacy of ATM for the treatment of attention, set-shifting, information processing speed and working memory deficits in cognitively impaired, non-demented patients with PD. The primary outcome for this study is the Global Treatment effect (GTE) at 10 weeks of combined ATM sensitive neuropsychological measures. Secondary outcomes are a set of neuropsychological measures that we hypothesize are not sensitive to treatment with ATM.", 
            "measure": "Neuropsychological Testing Battery", 
            "safety_issue": "No", 
            "time_frame": "twice within 12 week period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738191"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of South Carolina", 
            "investigator_full_name": "Vanessa Hinson", 
            "investigator_title": "Director, Movement Disorders Program", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To examine the safety of ATM in patients with PD. Safety will be determined through assessments of Vital Signs, Unified Parkinson's Disease Rating Scale (UPDRS), adverse events, Non motor symptom scale (NMSS), comprehensive metabolic panel, and ECG.", 
            "measure": "Safety measures", 
            "safety_issue": "Yes", 
            "time_frame": "5 visits throughout 12 weeks"
        }, 
        "source": "Medical University of South Carolina", 
        "sponsors": {
            "collaborator": {
                "agency": "Michael J. Fox Foundation for Parkinson's Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Medical University of South Carolina", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}